Morphine Sulfate
Injection · trading as Infumorph 200
Current Active — Day 3114
Lower impact — Multiple manufacturers (6 known suppliers) produce this drug, which may allow alternative sourcing.
FDA shortage record
- Substance
- Morphine Sulfate
- Brand name
- Infumorph 200
- Manufacturers / suppliers
-
- Hikma Pharmaceuticals USA Inc.
- Hikma Pharmaceuticals USA, Inc.
- Dosage form
- Injection
- Presentation
- Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)
- Route(s)
- EPIDURAL, INTRATHECAL
- Therapeutic category
- Analgesia/Addiction
- Package NDC
0641-6039-01- Initially posted
- 11/03/2017
- Days on shortage list
- 3114
- Current FDA status
- Current
- Shortage entries (current dataset)
- 6 records for Morphine Sulfate — repeat offender
Reason and context
Reason reported: Demand increase for the drug
Product temporarily on backorder. Additional lots will be available in the May 2026 timeframe.
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 800-631-2174.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
db9ac9e3-d761-4a99-9f34-4946ebe8f255). - FDA UNII identifier:
X3P646A2J0. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.